Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. - Biomarkers for Angiogenesis in Renal Cell Carcinoma and NET.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35791

Enrollment

Registered

2011-07-06

Start date

2011-07-12

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clear cell renal cell carcinoma kidney cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older 2. Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases 3. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Use of L-dopa or SSRI 2. Patients with a second primary malignancy

Design outcomes

Primary

Measure	Time frame
Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.	—

Secondary

Measure	Time frame
Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours before start of a treatment cycle and during a treatment cycle.	—

Countries

Netherlands

Outcome results